The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted July 23–24, 2026, to recommend six of seven peptides for inclusion on the list of substances that may be compounded in bulk by outsourcing facilities and compounding pharmacies. If adopted by the FDA, the recommendations would allow the continued compounding of several widely used peptide products that currently sit in a regulatory gray zone — outside the agency's formal drug approval pathway but commonly prescribed in practice.

The committee reviewed seven peptides over the two-day meeting. Six received favorable votes: BPC-157, KPV, TB-500, MOTS-c, and two additional peptides not individually identified in the available reporting. The sole peptide the panel declined to recommend was emideltide, which failed on a 7–6 vote against, with one abstention (Fierce Pharma).

Several of the favorable votes were narrow. BPC-157 passed on an 8–6 vote, as did KPV (STAT News). ABC News characterized the overall set of recommendations as a narrow endorsement (ABC News). The Washington Post, the most recently published source on the overall vote tallies, confirmed that six of seven peptides received the panel's recommendation (Washington Post).

BPC-157, one of the more widely recognized peptides in the compounding space, was proposed for the treatment of ulcerative conditions (Washington Post). KPV, TB-500, and MOTS-c were among the other peptides recommended for the compounding list (ABC News). The full identities of the remaining two recommended peptides were not specified in the available source reporting.

The meeting itself underwent scheduling adjustments before it convened. Originally announced on June 18, 2026, the session times were subsequently changed. The July 23 session, which began with a Call to Order at 8:00 a.m. Eastern Time, saw its end time extended from 4:30 p.m. to 6:20 p.m. Eastern (FDA). FDA published a meeting roster and a questions document for the morning session addressing whether certain substances should be reviewed for inclusion on the bulk compounding list (FDA roster; FDA questions document).

The PCAC's role is advisory. Its recommendations go to FDA, which makes the final determination on which substances appear on the bulk drug substances list for compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The panel's votes do not themselves change compounding practice; they inform FDA's rulemaking process. Think of the committee as a jury that issues a recommendation — the judge, here the FDA, still has to rule.

The broader context here is that peptides occupy a contested space in the compounding market. Peptides are short chains of amino acids that can act as signaling molecules in the body. Many of these substances are not FDA-approved drugs but are nonetheless widely compounded and prescribed, particularly in wellness, anti-aging, and sports medicine channels. The 503A/503B bulk substances list functions as the regulatory gateway: substances on the list can be lawfully compounded in bulk, while those excluded effectively lose that pathway. For compounding pharmacies and outsourcing facilities, inclusion means continued access to raw material for formulation. For branded or investigational peptide developers, inclusion means competing against compounded versions of molecules that may not have undergone the agency's full approval process.

The narrowness of the votes, particularly the 8–6 tallies on BPC-157 and KPV, signals that the scientific evidence base for these substances is genuinely contested within the advisory committee itself. The emideltide rejection, with its split 7–6–1 outcome, fits the same pattern. When a panel this divided issues a recommendation, the signaling value to FDA is weaker than a lopsided vote would carry. The agency retains full discretion to accept, modify, or reject the panel's guidance, and split votes historically give regulators more latitude to depart from committee recommendations.

For market participants, the practical question is how quickly FDA moves to codify these recommendations, and whether the agency accepts all six or exercises selectivity given the narrow margins. The compounding supply chain, telehealth prescribers, and patients currently using these products all face a transition risk if FDA chooses to diverge from the panel's advice. Conversely, formal inclusion on the list would provide a measure of regulatory durability for compounded peptide products that, to date, have operated under provisional status pending the agency's determinations.

No timeline for FDA's final decision on these substances was specified in the available reporting.